Use of hydroxyapatite in spine surgery.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11716019.
- Also identified by PMC identifier 3611554.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hydroxyapatite- (HA-)based ceramics have been evaluated for a variety of applications in spinal surgery, utilizing in vivo animal models and human clinical series. In vivo animal studies have shown efficacy for these materials as a bone graft substitute in interbody fusions and as a bone graft extender or bioactive osteoinductive material carrier in posterolateral lumbar fusions. Clinically, HA ceramic has been shown to be effective as a bone graft extender in posterior spinal fusion surgery for childhood scoliosis, and as a structural bone graft substitute in anterior cervical spine fusions. As an osteoconductive material, it appears to function best as a bone graft extender or carrier for an osteoinductive bone growth factor rather than as a stand-alone bone graft substitute in nonstructural clinical applications. Injectable HA ceramics also hold promise as biocompatible and bioresorbable materials for use in spinal screw fixation strength augmentation and in minimally invasive vertebral body strength augmentation either following fracture or prophylactically in osteoporotic vertebrae.
Medical subject headings
- Biocompatible Materials
- Durapatite
- Orthopedic Procedures
- Spinal Fusion
- Spine